Search Within

Helena Alexandra Yu

Formats
  1. Meeting Abstract (160)
  2. Journal Article (105)
  3. Editorial (9)
  4. Review (7)
  5. Book Section (2)
  6. Conference Paper (1)
  7. Correspondence (1)
Groups
  1. Department of Medicine (285)
  2. Solid Tumor Oncology Division (285)
  3. Thoracic Oncology (285)
  4. GSK Faculty (119)
  5. Department of Pathology and Laboratory Medicine (102)
  6. Human Oncology and Pathogenesis Program (100)

More Groups

People
  1. Gregory Riely (107)
  2. Mark Kris (94)
  3. Marc Ladanyi (71)
  4. Charles Rudin (57)
  5. Maria Arcila (55)
  6. Alexander Drilon (36)

More People

Years
  1. 2025 (14)
  2. 2024 (28)
  3. 2023 (30)
  4. 2022 (33)
  5. 2021 (30)
  6. 2020 (15)

More Years

Publications
  1. Journal of Clinical Oncology (73)
  2. Journal of Thoracic Oncology (62)
  3. Annals of Oncology (26)
  4. Clinical Cancer Research (18)
  5. International Journal of Radiation Oncology, Biology, Physics (14)
  6. Cancer Discovery (9)

More Publications

Publishers
  1. Elsevier Inc. (84)
  2. American Society of Clinical Oncology (82)
  3. American Association for Cancer Research (31)
  4. Oxford University Press (30)
  5. Nature Publishing Group (11)
  6. Elsevier Science, Inc. (7)

More Publishers

Results (285)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Stage at diagnosis as a prognostic marker for patients with KRAS-mutant metastatic lung adenocarcinomas
    Meeting Abstract

    Yu, H. A.; Hellmann, M. D.; Sima, C. S.; Busby, N.; Rodriguez, K.; Riely, G. J.; Kris, M. G.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Concurrent molecular alterations in KRAS-mutant lung adenocarcinomas and effects on overall survival
    Meeting Abstract

    Riely, G. J.; Eng, J.; Yu, H. A.; Hsu, M.; Kris, M. G.; Borsu, L.; Cavatore, M.; Yannes, A.; Brzostowski, E.; Casanova, J.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Alterations in two oncogenic drivers: Impact of concurrent PIK3CA or AKT1 mutations in patients with oncogene-driven lung adenocarcinomas
    Meeting Abstract

    Eng, J.; Hellmann, M. D.; Woo, K.; Sima, C. S.; Yu, H. A.; Arcila, M. E.; Ladanyi, M.; Kris, M. G.; Drilon, A. E.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib
    Journal Article

    Hellmann, M. D.; Reva, B.; Yu, H.; Rusch, V. W.; Rizvi, N. A.; Kris, M. G.; Arcila, M. E.
    Journal of Thoracic Oncology (2014)

    Fulltext@MSK | Save
  • Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer
    Meeting Abstract

    Soria, J.; Sequist, L. V.; Goldman, J. W.; Wakelee, H. A.; Gadgeel, S. M.; Varga, A.; Yu, H. A.; Solomon, B. J.; Ou, S. H.; Papadimitrakopoulou, V.; more...
    European Journal of Cancer (2014)

    Fulltext@MSK | Save
  • Pattern of failure in metastatic EGFR-mutant NSCLC treated with erlotinib: A role for upfront radiation therapy?
    Meeting Abstract

    Patel, S.; Rimner, A.; Foster, A.; Zhang, Z.; Woo, K. M.; Yu, H. A.; Riely, G. J.; Wu, A. J.
    International Journal of Radiation Oncology, Biology, Physics (2014)

    Fulltext@MSK | Save
  • Risk of brain metastasis in EGFR-mutant NSCLC treated with erlotinib: A role for prophylactic cranial irradiation?
    Meeting Abstract

    Patel, S.; Rimner, A.; Foster, A.; Zhang, Z.; Woo, K. M.; Yu, H. A.; Riely, G. J.; Wu, A. J.
    International Journal of Radiation Oncology, Biology, Physics (2014)

    Fulltext@MSK | Save
  • EGFR exon 20 alterations in lung adenocarcinomas and their impact on overall survival and response to EGFR TKI
    Meeting Abstract

    Naidoo, J.; Sima, C. S.; Rodriguez, K.; Busby, N.; Arcila, M. E.; Yu, H. A.
    International Journal of Radiation Oncology, Biology, Physics (2014)

    Fulltext@MSK | Save
  • Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors
    Journal Article

    Yu, H. A.; Riely, G. J.; Lovly, C. M.
    Clinical Cancer Research (2014)

    Fulltext@MSK | Save
  • Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements?
    Journal Article

    Halpenny, D. F.; Riely, G. J.; Hayes, S.; Yu, H.; Zheng, J.; Moskowitz, C. S.; Ginsberg, M. S.
    Lung Cancer (2014)

    Fulltext@MSK | Save